Clinical Trial ofMGMT(P140K)Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors-Reference-Cited by-同舟云学术

Clinical Trial ofMGMT(P140K)Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors

Published:2018-08 Issue:8 Volume:29 Page:874-885
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Kramer Belinda¹,Singh Radhika¹,Wischusen Jessica¹,Dent Rebecca¹,Rush Amanda¹,Middlemiss Shiloh¹,Ching Yu Wooi¹,Alexander Ian E.²³,McCowage Geoffrey⁴

Affiliation:

1. Children's Cancer Research Unit, The Children's Hospital at Westmead, Westmead, Australia.

2. Gene Therapy Research Unit, Children's Medical Research Institute, Westmead, Australia and the Children's Hospital at Westmead, Westmead, Australia.

3. The University of Sydney, Discipline of Paediatrics and Child Health, Westmead, Australia.

4. Children's Cancer Centre, The Children's Hospital at Westmead, Westmead, Australia.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.2017.235

Reference37 articles.

1. Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease

2. Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy

3. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

4. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

5. Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy;Current Neuropharmacology;2024-01

2. Repair Mechanisms and Initiation in Carcinogenesis;Reference Module in Biomedical Sciences;2024

3. MGMT et sensibilité au temozolomide;Bulletin du Cancer;2021-12

4. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor–Modified Hematopoietic Stem Cells for Cancer Therapy;Human Gene Therapy;2019-04